Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 8/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2240153 | 0.93 | ALDH1A1 (0.39) | HDAC1HDAC8HDAC6HDAC5RAB9A | |
| SCHEMBL2236534 | 0.92 | HDAC1 (0.38) | HDAC1HDAC8HDAC6HDAC5ALDH1A1 | |
| SCHEMBL2239299 | 0.90 | HDAC1 (0.36) | HDAC1HDAC8HDAC6HDAC5LMNA | |
| SCHEMBL6011888 | 0.90 | LMNA (0.34) | LMNARAB9AALDH1A1L3MBTL1MAPT | |
| SCHEMBL2236768 | 0.88 | GAA (0.36) | HDAC1HDAC8HDAC6HDAC5LMNA | |
| SCHEMBL2239265 | 0.87 | HDAC1 (0.39) | HDAC1HDAC8HDAC6HDAC5RAB9A | |
| SCHEMBL2234755 | 0.86 | HDAC1 (0.35) | HDAC1HDAC8HDAC6HDAC5ALDH1A1 | |
| SCHEMBL2237823 | 0.86 | HDAC1 (0.39) | HDAC1HDAC8HDAC6HDAC5ALDH1A1 | |
| SCHEMBL2238018 | 0.86 | HDAC1 (0.34) | HDAC1HDAC8HDAC6HDAC5RAB9A | |
| SCHEMBL2238014 | 0.85 | ALDH1A1 (0.36) | HDAC1HDAC8HDAC6HDAC5LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | claimed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | claimed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | claimed |
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | ASTELLAS PHARMA INC. (JP) | 2011-08-18 | — | — | US | disclosed |
| EP-1857108-B1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | ASTELLAS PHARMA INC (JP) | 2010-12-08 | — | — | EP | disclosed |
| EP-1844775-B1 | THERAPEUTIC AGENT FOR THE TREATMENT OF HERPES PROGENITALIS AFTER DEVELOPMENT OF LESIONS | ASTELLAS PHARMA INC (JP) | 2010-08-11 | — | — | EP | disclosed |
| EP-1844776-B1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC (JP) | 2010-04-28 | — | — | EP | disclosed |
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ASTELLAS PHARMA INC. (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | ASTELLAS PHARMA INC. (JP) | 2009-02-12 | — | — | US | disclosed |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | ASTELLAS PHARMA INC. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-7465748-B2 | Antiherpesvirus drugs; great pharmacokinetics, good antivirus activity when administered orally at a low dose, high safety profile, less mutagenic concerns; N-(2,6-dimethylphenyl)-N-(2-{[4-(1,3-oxazol-4-yl)phenyl]amino)-2-oxoethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide | ASTELLAS PHARMA INC. (JP) | 2008-12-16 | — | — | US | disclosed |
| EP-1857108-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELATED DISEASE | Astellas Pharma Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| EP-1844775-A1 | THERAPEUTIC AGENT FOR HERPES PROGENITALIS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| EP-1844776-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | Astellas Pharma Inc. (JP) | 2007-10-17 | — | — | EP | disclosed |
| US-20060229295-A1 | Amide derivatives | ASTELLAS PHARMA INC.AND RATIONAL DRUG DESIGN (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1652843-A1 | AMIDE DERIVATIVES | Astellas Pharma Inc. (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6903125-B2 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-06-07 | — | — | US | disclosed |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048310-A1 | AGENT FOR PREVENTION/TREATMENT OF DISEASE CAUSED BY ACYCLOVIR-RESISTANT HERPESVIRUS | ZC3HAV1, ZC3HAV1L, GRIK2 | HDAC1 6/4885HDAC8 12/4885HDAC6 758/4885 |
| US-20050032855-A1 | Tetrahydro-2H-thiopyran-4-carboxamide derivative | TPMT, RPL35, TYMP | HDAC1 39/4885HDAC8 32/4885HDAC6 1368/4885 |
| US-20110201659-A1 | AGENT FOR PREVENTING OR TREATING ZOSTER-ASSOCIATED PAIN | GAP43, TRPV1, ACHE | HDAC1 1277/4885HDAC8 1199/4885HDAC6 771/4885 |
| US-20060229295-A1 | Amide derivatives | VAC14, HDAC8, ZC3HAV1 | HDAC1 7/4885HDAC8 2/4885HDAC6 364/4885 |
| US-20090042915-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR HERPESVIRUS-RELEATED DISEASE | RECQL, DNA2, DHX35 | HDAC1 243/4885HDAC8 291/4885HDAC6 548/4885 |
| US-20090030049-A1 | MEDICAMENT FOR GENITAL HERPES | TK1, TYMP, RPL23 | HDAC1 261/4885HDAC8 117/4885HDAC6 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.